cancer study News
-
EPA places four IRIS assessments on hold pending review (HQ)
The U.S. Environmental Protection Agency (EPA) announced today that it is holding four of its ongoing IRIS (Integrated Risk Information System) assessments pending a review of some of the underlying studies used in the assessments. EPA conducts IRIS assessments to determine the impact of specific chemicals on human health. EPA is holding these assessments due to a report from the National ...
-
Pesticides linked to childhood brain cancers
There is much grey matter surrounding causes of brain cancer in children, but there is increasing evidence indicating that a culprit may be pre-birth pesticide exposure. In a new study released by the National Institute of Health Sciences, herbicide use appeared to cause an elevated risk for cancer. The study found that children living in homes where their parents use pesticides are twice as ...
-
Single Cell Sequencing: Transform Your Immunology and Cancer Research from Bulk to Single Cell Analysis
Single cell sequencing has transformed our ability to discern the cellular and molecular makeup of human immune systems and tissues in a unique manner with a level of precision that other “omic” technologies are unable to provide. Coupled with rigorous analysis, this technology is able to identify rare cell populations/subtypes and provide novel insights about pathways and thus ...
-
New EU research suggests chemicals may increase risk of breast cancer
Breast cancer has increased dramatically in Europe over the past 20 years, with a doubling of the number of cases in some countries over this time period. A recent report presented to the European Parliament suggests that by reducing our exposure to certain chemicals, the number of women who develop breast cancer could also be reduced. The report by UK researchers summarises the evidence for the ...
-
FlavourSpec feasibly detects hepatocellular carcinoma urinary biomarkers in clinical practice
The Imspex Group’s proprietary gas chromatography-ion mobility spectrometry (GC-IMS) technology was part of a ground-breaking cancer detection study that was recently carried out by a team of researchers from the University of Warwick, Coventry University and the University of Leicester. In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds ...
-
Five-Nation breast cancer study chooses agilent technologies microarrays as primary genomic screening tool
Agilent Technologies Inc. (NYSE: A) today announced that the United States-Latin American Cancer Research Network (US-LACRN) has selected Agilent Gene Expression microarrays and associated instruments for a major study of breast cancer in five Latin American nations. The researchers will use the microarrays over three years to study gene-expression profiles of 3,000 women with Stage 2 and Stage ...
-
Integrating Fusion Biopsies into Your Practice I
Compared to standard systematic biopsies, MRI-targeted fusion biopsies improve the detection of clinically significant prostate cancer. Studies have shown MRI can be a cost-effective and accurate first-line diagnostic tool for the early detection of prostate cancer. If the MRI is negative, patients may avoid biopsy, whereas positive results provide an action plan for biopsy and potential ...
-
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. Lung cancer is the leading cause of cancer death accounting for almost one quarter of annual ...
-
ELIAS Animal Health Adds Clinical Trial Site for ECI for the Treatment of Canine Osteosarcoma
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newlydiagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in ...
-
GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New ...
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation
The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. The largest interventional trial in dogs, it is sponsored by the Open Philanthropy Project, with additional support from Calviri, Inc., a biotech spinout from Arizona State University. The VACCS trial intends to enroll up to ...
By Calviri
-
New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
Study results presented at ASCO20 showed that the Recurrence Score results on core biopsies predict the likelihood of response to neoadjuvant chemotherapy Results are particularly relevant in the context of the Covid-19 pandemic which is causing the delay of elective surgeries across health systems worldwide Exact Sciences Corp. today announced results from three studies of the Oncotype DX ...
-
EPA announces plan of action to address four iris assessments
The U.S. Environmental Protection Agency (EPA) announced today its plan to address the four draft Integrated Risk Information System (IRIS) assessments that were placed on hold in June 2010, pending a review of some of the underlying studies relied on in the assessments. EPA conducts IRIS assessments to determine the potential impact of specific chemicals on people’s health. The four ...
-
First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work by an international consortium, SuppresSTEM which included Crown ...
-
Clinical Results Presented at PCF Retreat
Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University School of Medicine presented results from the first 10 participants at the 2021 Annual Prostate Cancer Foundation Scientific Retreat. The poster presented featured early results from “A Feasibility Study to Deplete Non-Essential Amino Acids in Patients ...
-
Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer
Kephera Diagnostics has been awarded a $1,999,961 million Phase II Small Business Innovative Research (SBIR) contract by the National Cancer Institute, an agency of the National Institutes of Health, for a test for liver fluke infection, the Company announced today. Kephera had previously received a $300,000 Phase I contract to develop and demonstrate the feasibility of its test. Liver flukes ...
-
NIEHS Scientists Identify the Immunity Proteins that cause a majority of DNA Damage in Several Types of Human Cancers
New research published online August 10 in the journal Nature Genetics found that a mutation-causing enzyme known at APOBEC3A (A3A) may be the main cause of mutations in certain cancers. Previous work from other groups implicated another APOBEC enzyme, known as APOBEC3B (A3B). Corresponding author Dmitry Gordenin, Ph.D., head of the NIEHS Mechanisms of Genome Dynamics Group, will be available ...
-
Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer ...
-
Study published in BJC shows strong performance of Tethis’ liquid biopsy test in early stage breast cancer
Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early breast cancer showing the analytical performance of the novel SBS® ...
By Tethis S.p.A
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you